Biotechnology is an exciting industry, where technology creates medicine tailored to individuals.


This is seen as the future of healthcare, as instead of being given one size fits all drugs patients can get treatments that will work better for them and fight diseases such as cancer in a way that increases their chances of survival.


As the West’s populations age, this will become even more important.


We interview Carl Harald Janson, the manager of International Biotechnology Trust and a qualified medical doctor. He explains what biotechnology is, how it works and what he looks for when investing in companies that could change healthcare over the next decades.


We also ask him about how this growth-focussed investment trust has started to pay investors a 4 per cent annual dividend.



This Is Money – The Investing Show Article


  • You are seeing this because you are accessing IBT’s website for the first time.


  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.


  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.


  • The material on this website is intended to be viewed only by persons resident in the EEA.


  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.


  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.


  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).